Skip to main content
PBLA logo

Panbela Therapeutics, Inc. (PBLA) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0002 $0.00 (0.00%)
Vol: 1.0K| 52-wk range: $0.0001 – $2.50
Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Panbela Therapeutics, Inc. (PBLA) trades at $0.0002. Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer treatment. Their lead product candidate, SBP-101, is undergoing clinical trials for metastatic pancreatic ductal adenocarcinoma. Sector: Healthcare.

Price as of · Last analyzed: Mar 16, 2026
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer treatment. Their lead product candidate, SBP-101, is undergoing clinical trials for metastatic pancreatic ductal adenocarcinoma.

Analyst Coverage for PBLA: PBLA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • NVO · Novo Nordisk A/S · 87 /100
  • VRTX · Vertex Pharmaceuticals Incorporated · 90 /100
  • REGN · Regeneron Pharmaceuticals, Inc. · 95 /100

See all scored stocks →

Panbela Therapeutics, Inc. (PBLA) Healthcare & Pipeline Overview

CEOJennifer K. Simpson
Employees8
HeadquartersWaconia, US
IPO Year2017

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for cancer, particularly pancreatic cancer. Their lead product, SBP-101, is in Phase Ia/Ib clinical trials. Trading on the OTC market, the company faces unique risks and liquidity challenges compared to exchange-listed peers.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 16, 2026

What Is the Investment Thesis for PBLA?

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Panbela Therapeutics presents a high-risk, high-reward investment opportunity characteristic of early-stage biotech companies. The primary value driver is the successful development and commercialization of SBP-101, targeting pancreatic cancer. Positive Phase Ia/Ib clinical trial results for SBP-101 would serve as a significant catalyst, potentially leading to increased investor interest and strategic partnerships. Conversely, clinical trial failures or regulatory setbacks could severely impact the company's valuation. The company's OTC listing introduces additional liquidity and transparency concerns. Investors should carefully weigh the potential upside against the inherent risks associated with clinical-stage biopharmaceutical companies before investing.

Based on FMP financials and quantitative analysis

PBLA Key Highlights

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Panbela Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics, particularly for pancreatic cancer.

  • The company's lead product candidate, SBP-101, is currently in Phase Ia/Ib clinical trials for metastatic pancreatic ductal adenocarcinoma.
  • Panbela Therapeutics operates with a small team of 7 employees, reflecting a lean operational structure.
  • The company trades on the OTC market, indicating higher risk and lower liquidity compared to exchange-listed companies.
  • Panbela Therapeutics changed its name from Sun BioPharma, Inc. in December 2020 to reflect its evolving focus.

Who Are PBLA's Competitors?

PBLA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
NVO Novo Nordisk A/S $39.43 -3.12% $174B 87 5-pillar
VRTX Vertex Pharmaceuticals Incorporated $536.45 +0.42% $136B 90 5-pillar
REGN Regeneron Pharmaceuticals, Inc. $945.53 -1.28% $97.8B 95 5-pillar
ARGX argenx SE $942.04 +0.08% $59.2B 96 5-pillar
RPRX Royalty Pharma plc $68.67 -0.01% $39.5B 73 5-pillar
GMAB Genmab A/S $50.97 -1.91% $31.4B 72 5-pillar
UTHR United Therapeutics Corporation $577.34 -1.16% $24.6B 97 5-pillar
INCY Incyte Corporation $117.80 -1.08% $24.0B 91 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PBLA's Key Strengths?

Focus on a high unmet need in pancreatic cancer.

  • Lead product candidate, SBP-101, in clinical trials.
  • Experienced management team with expertise in drug development.
  • Proprietary technology platform for developing novel cancer therapeutics.

What Are PBLA's Weaknesses?

Limited financial resources and reliance on external funding.

  • High risk of clinical trial failure.
  • Small team size and limited infrastructure.
  • OTC market listing indicating higher risk and lower liquidity.

What Are the Key Risks for PBLA?

Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

  • Failure of SBP-101 in clinical trials.
  • Regulatory delays or rejection of SBP-101.
  • Competition from other companies developing cancer therapeutics.
  • Limited financial resources and reliance on external funding.
  • OTC market listing indicating higher risk and lower liquidity.

What Threats Does PBLA Face?

  • Competition from larger pharmaceutical companies with more resources.
  • Regulatory hurdles and delays in drug approval.
  • Patent challenges and intellectual property disputes.
  • Negative publicity or safety concerns related to SBP-101.

What Are PBLA's Competitive Advantages?

  • Patent protection for SBP-101 and other pipeline assets.
  • Proprietary knowledge and expertise in cancer drug development.
  • Clinical data demonstrating the efficacy and safety of SBP-101.
  • Potential for orphan drug designation for SBP-101 in pancreatic cancer.

What Does PBLA Do?

Panbela Therapeutics, Inc., established in 2011 and based in Waconia, Minnesota, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Originally incorporated as Sun BioPharma, Inc., the company rebranded to Panbela Therapeutics, Inc. in December 2020 to reflect its evolving focus. The company's primary focus is on diseases affecting the pancreas, including pancreatitis and pancreatic cancer. Their research extends to other cancer indications, such as neoadjuvant pancreatic cancer, colorectal cancer, and ovarian cancer. Panbela's lead product candidate, SBP-101, is currently in Phase Ia/Ib clinical trials for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. Panbela operates with a small team of 7 employees, emphasizing a lean and focused approach to drug development. The company aims to address unmet medical needs in cancer therapy through the development of novel and disruptive therapeutics.

What Products and Services Does PBLA Offer?

  • Develops disruptive therapeutics for cancer treatment.
  • Focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer.
  • Conducts clinical trials for its lead product candidate, SBP-101.
  • Targets metastatic pancreatic ductal adenocarcinoma with SBP-101.
  • Explores the potential of SBP-101 in other cancer indications, such as colorectal and ovarian cancer.
  • Operates as a clinical-stage biopharmaceutical company.

How Does PBLA Make Money?

  • Develops and patents novel cancer therapeutics.
  • Conducts preclinical and clinical trials to demonstrate safety and efficacy.
  • Seeks regulatory approval from the FDA and other regulatory agencies.
  • Potentially partners with larger pharmaceutical companies for commercialization or out-licensing.

What Industry Does PBLA Operate In?

Panbela Therapeutics operates within the competitive biotechnology industry, focusing on oncology. The oncology market is experiencing substantial growth, driven by an aging population and advancements in cancer diagnostics and treatments. Pancreatic cancer, in particular, represents a significant unmet medical need, making it a key target for biopharmaceutical companies. Competitors include companies like Advantagene, Inc. (ADVT), BioBlast Pharma Ltd. (BBBT), and others developing therapies for cancer. Panbela's success depends on its ability to navigate the complex regulatory landscape and demonstrate clinical efficacy.

Who Are PBLA's Key Customers?

  • Patients with cancer, particularly pancreatic cancer.
  • Oncologists and other healthcare professionals who treat cancer patients.
  • Hospitals and cancer centers that provide cancer treatment services.
  • Potential pharmaceutical partners interested in licensing or acquiring Panbela's products.
Model self-rating on this text: 69% (not a measure of the evidence) Updated: Mar 16, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage
FY2026 est

Forward Outlook

Wall Street analysts project Panbela Therapeutics, Inc. revenue of about $8.4M for fiscal 2026, with EPS near $-3.43.

ROE 396%

Key Financial Metrics

Return on equity for Panbela Therapeutics, Inc. stands at 396.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.25 means current liabilities exceed short-term assets, a liquidity point worth watching.

F-Score 4/9

Financial Health

Panbela Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.

3/8 beats

Earnings Track Record

Panbela Therapeutics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 49.3% below estimates on average.

Company Profile

Panbela Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waconia, US. The company is led by CEO Jennifer K. Simpson. PBLA has traded publicly since 2017.

PBLA Latest News

No recent news available for PBLA.

PBLA Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PBLA.

Price Targets

Wall Street price target analysis for PBLA.

PBLA MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PBLA; grades run from A+ (80-100) to F (below 30).

Leadership: Jennifer K. Simpson

CEO

Jennifer K. Simpson serves as the CEO of Panbela Therapeutics, leading a team of 7 employees. Her background includes experience in the biopharmaceutical industry, with a focus on drug development and clinical trials. She has a proven track record of managing and advancing early-stage drug candidates through the clinical development process. Her expertise spans across various therapeutic areas, including oncology. Simpson's leadership is crucial for guiding Panbela through its clinical trials and potential commercialization phases.

Track Record: Under Jennifer K. Simpson's leadership, Panbela Therapeutics has focused on advancing SBP-101 through clinical trials. She has overseen the company's strategic direction, including its focus on pancreatic cancer and other cancer indications. Her key decisions have included prioritizing the development of SBP-101 and seeking strategic partnerships to support the company's growth. She has successfully navigated the challenges of operating a small, clinical-stage biopharmaceutical company.

PBLA OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that Panbela Therapeutics may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited or no financial disclosure, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may be subject to greater price volatility and risk. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.

  • OTC Tier: OTC Other
Liquidity: As an OTC-listed stock, Panbela Therapeutics likely experiences lower trading volume and wider bid-ask spreads compared to exchange-listed companies. This can make it more difficult to buy or sell shares quickly and at desired prices. The limited liquidity can also contribute to increased price volatility. Investors should be aware of these liquidity challenges and consider using limit orders to manage their risk.
OTC Risk Factors:
  • Limited financial disclosure and transparency.
  • Lower trading volume and liquidity.
  • Greater price volatility.
  • Potential for fraud or manipulation.
  • Higher risk of delisting or going out of business.
Due Diligence Checklist:
  • Verify the company's registration and regulatory filings.
  • Review the company's financial statements (if available).
  • Assess the company's management team and their experience.
  • Understand the company's business model and competitive landscape.
  • Evaluate the company's intellectual property and patent protection.
  • Monitor news and press releases for any red flags.
  • Consult with a qualified financial advisor.
Legitimacy Signals:
  • Focus on clinical-stage drug development.
  • Lead product candidate in Phase Ia/Ib clinical trials.
  • Dedicated to developing cancer therapeutics.
  • Management team with experience in the biopharmaceutical industry.
  • Presence of a website and investor relations materials.

What Investors Ask About Panbela Therapeutics, Inc. (PBLA) — Healthcare

What does Panbela Therapeutics, Inc. do?

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing disruptive therapeutics for the treatment of patients with cancer.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on publicly available sources and may be subject to change.
  • OTC market data may be limited and less reliable than exchange-listed data.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives